Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Neonatology

Free Subscription Articles published in Eur Respir J Retrieve available abstracts of 54 articles: HTML format

Single Articles

June 2026
1. LEIGH MW, Shapiro AJ, Chawla KK, Hazucha MJ, et al
   Tidal breathing nasal nitric oxide measurement as a test for primary ciliary dyskinesia in young children.
   Eur Respir J. 2026;67:2501540.
   PubMed     Abstract available
   
   
   May 2026
2. BORRELLI A, Venturini A, Guidone D, De Santis M, et al
   Rescue of the CFTR chloride channel with nonsense mutations is markedly improved under inflammatory conditions.
   Eur Respir J. 2026;67:2501171.
   PubMed     Abstract available
   
   
   April 2026
3. BORIE R, Mageau A, Guerin C, Weiss M, et al
   Premature hair graying in patients with pulmonary fibrosis and relatives is suggestive of pathogenic variants in telomere related genes.
   Eur Respir J. 2026 Apr 23:2600093. doi: 10.1183/13993003.00093-2026.
   PubMed    
   
   
   March 2026
4. GE E, Yu C, Lavigne E, Villeneuve PJ, et al
   Early-life greenness and childhood asthma and allergic rhinitis: An Ontario birth cohort study.
   Eur Respir J. 2026 Mar 12:2502272. doi: 10.1183/13993003.02272-2025.
   PubMed    
   
   
   February 2026
5. NUSSSTEIN H, Urbantat RM, Fentker K, Loewe A, et al
   Changes in sputum viscoelastic properties and airway inflammation in primary ciliary dyskinesia are comparable to cystic fibrosis on elexacaftor/tezacaftor/ivacaftor therapy.
   Eur Respir J. 2026;67:2500616.
   PubMed     Abstract available
   
   
   
6. CUINAT S
   SRRM2 and neuroendocrine cell hyperplasia of infancy: connecting neurodevelopment to the lungs.
   Eur Respir J. 2026;67:2501869.
   PubMed    
   
   
   
7. RAPP CK, Rodler J, Mauss-Schwarzer K, Gothe F, et al
   Persistent tachypnoea of infancy (PTI/NEHI) and obesity in SRRM2-related developmental disorder.
   Eur Respir J. 2026;67:2502135.
   PubMed    
   
   
   January 2026
8. FATHIMA P, Pan E, Marsh J, Shanthikumar S, et al
   Characteristics, treatment and lung function outcomes of pulmonary exacerbations in cystic fibrosis: insights from the BEAT-CF cohort.
   Eur Respir J. 2026;67:2501349.
   PubMed     Abstract available
   
   
   December 2025
9. GRAY DM, Ullah A, Chaya S, Jacobs C, et al
   Lung function trajectories and determinants from birth to 6-years in an African birth cohort: extending trajectories through infancy using oscillometry.
   Eur Respir J. 2025 Dec 5:2500729. doi: 10.1183/13993003.00729-2025.
   PubMed     Abstract available
   
   
   
10. HALLE O, Graeber SY, Kontsendorn J, Kessemeier C, et al
    Reduction of systemic inflammation by elexacaftor/tezacaftor/ivacaftor correlates with lung function improvement in cystic fibrosis.
    Eur Respir J. 2025;66:2500150.
    PubMed     Abstract available
    
    
    
11. EHRHARDT H, Staude B, Abman SH
    Novel pathomechanisms of ventilator-induced neonatal lung injury: new targets to overcome ongoing challenges.
    Eur Respir J. 2025;66:2501672.
    PubMed    
    
    
    October 2025
12. HIRANI D, Selle J, Wagde V, Klymenko O, et al
    Targeting IL6-Edn1-FoxO1 axis enables lung growth in mechanically ventilated newborn mice.
    Eur Respir J. 2025 Oct 9:2401580. doi: 10.1183/13993003.01580-2024.
    PubMed     Abstract available
    
    
    September 2025
13. LOUVRIER C, Soreze Y, Mesinele J, de Becdelievre A, et al
    De novo SRRM2 variants in neuroendocrine cell hyperplasia of infancy and persistent tachypnea of infancy.
    Eur Respir J. 2025 Sep 18:2500777. doi: 10.1183/13993003.00777-2025.
    PubMed     Abstract available
    
    
    August 2025
14. PLANT BJ, Einarsson GG, Deasy KF, Dahly D, et al
    Cystic Fibrosis Microbiome-directed Antibiotic Therapy Trial in Exacerbations Results Stratified (CFMATTERS): results of a multicentre randomised controlled trial.
    Eur Respir J. 2025;66:2402443.
    PubMed     Abstract available
    
    
    July 2025
15. MALL MA, Wainwright CE, Legg J, Chilvers M, et al
    Elexacaftor/tezacaftor/ivacaftor in children aged >/=6 years with cystic fibrosis heterozygous for F508del and a minimal function mutation: results from a 96-week open-label extension study.
    Eur Respir J. 2025;66:2402435.
    PubMed     Abstract available
    
    
    June 2025
16. RATJEN F, Stanojevic S, Gunawardena T, Eckford PDW, et al
    Relationship between theratyping in nasal epithelial cells and clinical outcomes in people with cystic fibrosis.
    Eur Respir J. 2025;65:2401855.
    PubMed     Abstract available
    
    
    January 2025
17. MCEVOY CT, MacDonald KD, Shorey-Kendrick LE, Davies MH, et al
    Nasal CPAP increases alveolar number in a rhesus monkey model of moderate prematurity.
    Eur Respir J. 2025 Jan 16:2400727. doi: 10.1183/13993003.00727-2024.
    PubMed     Abstract available
    
    
    
18. DIMOPOULOS K, Constantine A
    Treat-and-repair: a simple but powerful term for a complex multimodal approach in patients with pulmonary arterial hypertension associated with congenital heart disease.
    Eur Respir J. 2025;65:2402022.
    PubMed    
    
    
    
19. FOUZAS S, Dimitriou G
    Respiratory oscillometry in neonates and small infants: has the time come?
    Eur Respir J. 2025;65:2402242.
    PubMed    
    
    
    
20. IVY D, Rosenzweig EB, Abman SH, Beghetti M, et al
    Reply to: Treat-and-repair: a simple but powerful term for a complex multimodal approach in patients with pulmonary arterial hypertension associated with congenital heart disease.
    Eur Respir J. 2025;65:2402127.
    PubMed    
    
    
    
21. WERTHAMMER JW, Gozal D
    The 10-year temporal evolution of respiratory support and associated outcomes in extremely premature infants: betting on a favourable forecast for the next decade.
    Eur Respir J. 2025;65:2402194.
    PubMed    
    
    
    
22. MOISEENKO A, Sinadinos A, Sergijenko A, Pineault K, et al
    Pharmacological and pre-clinical safety profile of rSIV.F/HN, a hybrid lentiviral vector for cystic fibrosis gene therapy.
    Eur Respir J. 2025;65:2301683.
    PubMed     Abstract available
    
    
    November 2024
23. LOFBERG L, Abrahamsson T, Bjorklund LJ, Hellstrom Westas L, et al
    Respiratory support and bronchopulmonary dysplasia in infants born at 22-26 weeks gestation in Sweden, 2004-2007 and 2014-2016.
    Eur Respir J. 2024 Nov 7:2401203. doi: 10.1183/13993003.01203-2024.
    PubMed     Abstract available
    
    
    
24. LIN B, Gong J, Keenan K, Lin F, et al
    Genome-wide association study of susceptibility to Pseudomonas aeruginosa infection in cystic fibrosis.
    Eur Respir J. 2024;64:2400062.
    PubMed     Abstract available
    
    
    
25. CROMWELL EA, Ostrenga JS, Sanders DB, Morgan W, et al
    Impact of the expanded label for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del variant in the USA.
    Eur Respir J. 2024;64:2401146.
    PubMed     Abstract available
    
    
    October 2024
26. WANG G, Hallberg J, Merid SK, Kumar A, et al
    Body mass index trajectories from birth to early adulthood and lung function development.
    Eur Respir J. 2024 Oct 28:2400298. doi: 10.1183/13993003.00298-2024.
    PubMed     Abstract available
    
    
    
27. URBANTAT RM, Mall MA
    How many functioning ciliated airway epithelial cells are necessary for effective mucociliary clearance?
    Eur Respir J. 2024;64:2401573.
    PubMed    
    
    
    
28. WATERS V, Ratjen F
    Reply to: Oral corticosteroids for cystic fibrosis pulmonary exacerbation: seeking the future in the past.
    Eur Respir J. 2024;64:2401577.
    PubMed    
    
    
    
29. WATERS V, Quon B, Ratjen F
    Reply to: Steroids in cystic fibrosis exacerbations: are we picking the right patients?
    Eur Respir J. 2024;64:2401713.
    PubMed    
    
    
    
30. LIU Y, He KZ, Xu JF
    Oral corticosteroids for cystic fibrosis pulmonary exacerbation: seeking the future in the past.
    Eur Respir J. 2024;64:2401049.
    PubMed    
    
    
    
31. BEINART D, Forrester DL, Ramakrishnan S
    Steroids in cystic fibrosis exacerbations: are we picking the right patients?
    Eur Respir J. 2024;64:2401225.
    PubMed    
    
    
    September 2024
32. ZHU Z, Shibata R, Hoffman KL, Cormier J, et al
    Integrated nasopharyngeal airway metagenome and asthma genetic risk endotyping of severe bronchiolitis in infancy and risk of childhood asthma.
    Eur Respir J. 2024 Sep 26:2401130. doi: 10.1183/13993003.01130-2024.
    PubMed     Abstract available
    
    
    
33. REIX P, Chassagnon G
    The younger, the better: lessons learned from real-world studies on CFTR modulators in young children.
    Eur Respir J. 2024;64:2401178.
    PubMed    
    
    
    
34. STAHL M, Dohna M, Graeber SY, Sommerburg O, et al
    Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or two F508del alleles.
    Eur Respir J. 2024;64:2400004.
    PubMed     Abstract available
    
    
    
35. CHASSAGNON G, Burgel PR
    Reply: Reversal of structural abnormalities with elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: the earlier you start, the better the outcome will be!
    Eur Respir J. 2024;64:2401247.
    PubMed    
    
    
    
36. MIDDLETON PG, Simmonds NJ
    Reversal of cystic bronchiectasis with elexacaftor/tezacaftor/ivacaftor.
    Eur Respir J. 2024;64:2400929.
    PubMed    
    
    
    August 2024
37. IVY D, Rosenzweig EB, Abman SH, Beghetti M, et al
    Embracing the challenges of neonatal and paediatric pulmonary hypertension.
    Eur Respir J. 2024 Aug 29:2401345. doi: 10.1183/13993003.01345-2024.
    PubMed     Abstract available
    
    
    
38. VARGHESE NP, Austin ED, Galambos C, Mullen MP, et al
    An Interdisciplinary Consensus Approach to Pulmonary Hypertension in Developmental Lung Disorders.
    Eur Respir J. 2024 Aug 15:2400639. doi: 10.1183/13993003.00639-2024.
    PubMed     Abstract available
    
    
    July 2024
39. ZANNIN E, Rigotti C, Schulzke SM, Sindelar R, et al
    Early respiratory system reactance predicts respiratory outcomes in preterm infants: a retrospective, multicentre study.
    Eur Respir J. 2024 Jul 26:2400246. doi: 10.1183/13993003.00246-2024.
    PubMed     Abstract available
    
    
    
40. AGARWAL S, Jat KR, Gupta S, Sankar J, et al
    Video-based direct observation physiotherapy in children with cystic fibrosis: a randomised controlled trial.
    Eur Respir J. 2024;64:2400826.
    PubMed    
    
    
    June 2024
41. GOSS CH, VanDevanter DR
    Challenges to the optimisation of cystic fibrosis exacerbation treatment outcomes.
    Eur Respir J. 2024;63:2400858.
    PubMed    
    
    
    
42. WATERS V, Shaw M, Perrem L, Quon BS, et al
    A randomised trial of oral prednisone for cystic fibrosis pulmonary exacerbation treatment.
    Eur Respir J. 2024;63:2302278.
    PubMed     Abstract available
    
    
    May 2024
43. CAVERLY LJ, Ross BD, Dickson RP
    From gut to lung and back again: early life microbiota in cystic fibrosis.
    Eur Respir J. 2024;63:2400595.
    PubMed    
    
    
    April 2024
44. FURSTOVA E, Drevinek P, Novotna S, Libik M, et al
    Precision medicine in cystic fibrosis: predictive role of forskolin-induced swelling assay.
    Eur Respir J. 2024;63:2400156.
    PubMed    
    
    
    March 2024
45. FRAYMAN KB, Macowan M, Caparros-Martin J, Ranganathan SC, et al
    The Longitudinal Microbial and Metabolic Landscape of infant Cystic Fibrosis: The gut-lung axis.
    Eur Respir J. 2024 Mar 14:2302290. doi: 10.1183/13993003.02290-2023.
    PubMed     Abstract available
    
    
    
46. MCKONE EF
    Socioeconomic disparities in European cystic fibrosis outcomes: time to close the gap.
    Eur Respir J. 2024;63:2400328.
    PubMed    
    
    
    
47. XU X, Li JD, Green TJ, Wilson L, et al
    Neutrophil elastase-dependent cleavage of LTA4H alters its aminopeptidase activity in cystic fibrosis.
    Eur Respir J. 2024;63:2301512.
    PubMed     Abstract available
    
    
    
48. KEREM E, Orenti A, Adamoli A, Hatziagorou E, et al
    Cystic fibrosis in Europe: improved lung function and longevity - reasons for cautious optimism, but challenges remain.
    Eur Respir J. 2024;63:2301241.
    PubMed     Abstract available
    
    
    
49. WIELPUTZ MO, Mall MA
    Therapeutic improvement of CFTR function and reversibility of bronchiectasis in cystic fibrosis.
    Eur Respir J. 2024;63:2400234.
    PubMed    
    
    
    
50. CAZIER P, Chassagnon G, Dhote T, Da Silva J, et al
    Reversal of cylindrical bronchial dilatations in a subset of adults with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.
    Eur Respir J. 2024;63:2301794.
    PubMed     Abstract available
    
    
    February 2024
51. COHEN R, Shteinberg M
    Unravelling the "frequent exacerbator" phenotype in cystic fibrosis.
    Eur Respir J. 2024;63:2400068.
    PubMed    
    
    
    
52. HOUSTON CJ, Alkhatib A, Einarsson GG, Tunney MM, et al
    Diminished airway host innate response in people with cystic fibrosis who experience frequent pulmonary exacerbations.
    Eur Respir J. 2024;63:2301228.
    PubMed     Abstract available
    
    
    
53. DOONEY M, Saba T
    Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme.
    Eur Respir J. 2024;63:2301392.
    PubMed    
    
    
    
54. BURGEL PR
    Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme.
    Eur Respir J. 2024;63:2400233.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Neonatology is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum